Press Releases

  • Wednesday, May 27, 2015
  • Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy… more

  • Tuesday, May 12, 2015
  • Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015… more

  • Wednesday, May 28, 2014
  • Genelux Appoints George Vandeman and Thomas Zindrick to Board of Directors… more

  • Thursday, May 15, 2014
  • Genelux Corporation Announces Former Amgen, Abbott Executives to Succeed Dr. Aladar A. Szalay, as CEO, Chairman of the Board… more

  • Tuesday, February 11, 2014
  • Genelux Corporation Appoints John D. Prunty Chief Financial Officer… more

  • Monday, November 18, 2013
  • Genelux Corporation’s GL-ONC1 selected by Elsevier among its “Top 10 Oncology Projects to Watch”… more

    Thursday, June 27, 2013
    Genelux Corporation Appoints Stefan M. Manth, MD, as President & CEO, Genelux Europe…more

    Saturday, June 15, 2013
    Genelux Presents Abstracts at the 7th International Meeting on Replicating Oncolytic Virus Therapeutics in Quebec…more

    Thursday, May 30, 2013
    Genelux Corporation Presents Abstracts at 2013 ASCO Annual Meeting for Clinical Trials of GL-ONC1, Its Oncolytic Virus Lead Product Candidate…more

    Monday, February 11, 2013
    Virus Engineered to Express Melanin Offers New Possibilities to Diagnose and Treat Solid Tumor Cancers… more

    Thursday, February 5, 2013
    First Patient Treated in Genelux Phase I Trial with GL-ONC1 at Memorial Sloan Kettering Cancer Center… more

    Thursday, November 1, 2012
    Genelux Corporation Announces Early Results of a Phase I/II Clinical Trial of Virotherapeutic GL-ONC1 in Advanced Peritoneal Cavity Cancers…more

    Saturday, June 28, 2012
    Genelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer Patients… more

    Thursday, June 14, 2012
    Genelux Corporation Announces First Patient Dosed in Phase I Combination Clinical Trial of
    GL-ONC1… more

    Thursday, May 31, 2012
    Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers…more

    Wednesday, May 30, 2012
    Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, its Oncolytic Virus Lead Product Candidate …more

    Thursday, August 4, 2011
    Genelux Corporation Appoints Catherine J. Mackey, PhD to Board of Directors… more

    Monday, June 6, 2011
    Preliminary results of Phase I Clinical Trial involving Intravenous Administration of GL-ONC1 to Patients with Advanced Solid Tumor Cancers presented at ASCO… more

    Monday, January 24, 2011
    Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive…more

    Sunday, November 14, 2010
    Genelux Awarded Therapeutic Discovery Project Grant… more